petitive and purposeless movements varying in local tion and form but commonly involving the mouth, lips, tongue, andjaw (bucco-linguo-masticatory dyski nesia) and at times by choreoathetoid movements of the neck, trunk, or limbs. These movements are usual ly intensified by emotional tension or by voluntary movements of other muscle groups. They are reduced in intensity by sleep or drowsiness. Neuroleptic drugs that are causing the syndrome can temporarily reduce the dyskinesia, and the abnormal movements may be come more severe or appear for the first time after drug withdrawal or dose reduction (4) . Antiparkin sonian drugs fail to reduce the dyskineti~movements and can aggravate or uncover the tardive dyskinesia (5) . In many patients the syndrome is irreversible' in others it can sometimes be reversed by discontim;ing the neuroleptics (6) . When the condition is life-threat ening, as in rare cases of dyskinesias of the esophagus or diaphragm, piperazine-like neuroleptics (fluphena zine or haloperidol) can be given and antichoIineIgic drugs (antiparkinsonian or others) avoided.
Recent studies have shown that tardive dyskinesia occurs with alarming frequency among patients treated with neuroleptics (7,.8 ). Fann and associates (7) found that 36% of a samp1e of 204 patients treated with neuroleptics manifested the syndrome. At the present time, there is no treatment of tardive dyski nesia that is effective over a long period of time; most efforts are directed toward its prevention.
The Allan Memorial Institute maintains a special fol low-up clinic for the 10ng-term maintenance treatment of ~chizophrenic outpatients. The present study was d~slgned t? e~aluate the incidence and severity of tar dl'~e dyskmesia among 261 patients from this popu latIOn and to determine the relationship of the syn d~ome to various other factors. Whereas most pre VIOUS surveys of tardive dyskinesia were conducted in lo~-term wards of mental hospitals, this study dealt WIth a population of schizophrenic outpatients.
0002-953X179JOll0079/051$OO.50 @ 1979 American Psychiatric Association METHOD Patients are accepted in the special follow-up clinic after the primary hospital diagnosis of schizophrenia is confirmed by the psychiatrist in charge of the clinic. The diagnostic criteria used are similar to those of the National Institute of Mental Health-Psychophar macology Service Center Collaborative Study (9). SchizophrenIc patients who are not likely to need long term pharmacotherapy are not accepted in the clinic. During the two years before this study pharma cotherapy was under strict control, and the following principles were applied: the minimum therapeutic dose was given; a single neuroleptic was prescribed when ever possible; drugs were administered in a single dai ly dose or twice-daily regimen; procyclidine (Kema drin) was the only antiparkinsonian drug used; at tempts were made to withdraw the antiparkinsonian after three months of treatment; fluphenazine enan thate, an injectable long-acting drug, was given to pa tients who were resistant to other neuroleptics, those who could not be reJiedupon to take medication. and those with frequent relapses; fluphenazine hydro chloride was the only piperazine-type drug given orally; polypharmacy was avoided and antidepressant drugs; minor tranquilizers, and hypnotics were not prescribed; and,finally, medication was reviewed each time the patient came to the clinic.
The patients were examined by a neurologist who had not seen them before in random order on the day they came for their regular visit to the clinic. All pa tients were examined except for a smaIl percentage (less than 5%) who repeatedly failed to keep appoint ments. The neurologist completed a structured medi cal questionnaire,l carried out a complete neurological examination, and rated each· patient for the presence and severity of tardive dyskinesia and other extra pyramidal symptoms. The presence of tardive dyski . nesias was assessed according to a standard procedure that included the following routine neurological tests: 1) the patient's spontaneous behavior was observed while seated, standing, or walking, 2) since abnormal movements are. increased by voluntary movements of other muscle groups, the oral-facial region was ob served while the patient carried out the pronation-su pination tests of both hands as fast as possible and per formed rapid alternate movements of both wnsts and the finger-Dose-finger test, 3) the patient was asked to walk without shoes so that any choreoathetoid mOVe ments of the limbs could be noted, and 4) the patient was asked to copy a spiral with both hands and to sign tThe medical questionnaire covered the following items: I) family histotY of mental disease, epilepsy, abnonnal movements or tics, isease, 2} histotY of previous admission for or logical disorder, brain surgery, bead trauma (with or without skull fracture), meningitis, or coma, and histoxy or presence of abnonnal movements, tics, epilepsy, or venereal dis ease, 3) abnonnal laboratory results (VDRL or BBG), 4) history of loss of consciousness, headache, visual trouble (decreased vision), loss of balance or difficulty walking, or difficulty 5waIJowing or talking, and 5) history of alcoholism or drug abuse (LSD, barbitu rates, etc.).
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his or her name (since the test is performed under emo tional tension, this procedure may activate dyskinetic movements and thus sometimes uncover covert dyski nesias). In doubtful cases, the patient was asked to open his or her mouth while performing the pronation supination and alternate movement tests so that the tongue could be observed. Questionable cases of tar dive dyskinesia were not considered to be positive.
Dyskinetic movements were rated according to fre quency and amplitude on a 4-point scale (0-3) as fol lows: O=absent, 1 =mild but clearly present, 2=mod erate, and 3=severe. Abnormal movements in the lin gual, masticatory, and facial-labial areas and the trunk and extremities were rated separately.
Other extrapyramidal symptoms were also rated on a modified version of a specially designed extra pyramidal rating scale (10) . The following items were evaluated: expressive automatic movements (facial mask and speech), bradykinesia, rigidity oflimbs, gait and posture, tremor (oflimbs, head, chin, and tongue), akathisia, increased salivation, and dystonia. Both spontaneous tremors and those manifested when the patient extended both arms forward with palms down and eyes closed or performed the spiral test and hand writing were evaluated. Each item was rated on a 6 point scale ranging from normal to extremely severe.
In the same visit the patient was seen by one ofthree psychiatrists who rated the therapeutic response to treatment on a S-point scale (11) and overall severity of illness on a 7-point scale (11). The neurologist and psy chiatrists did not have access to each others' findings.
RESULTS
The study population consisted of 261 schizophrenic outpatients, 138 male and 123 female, ranging in age from 19 to 67 years. Table 1 shows the mean and stan-.' dard deviation for the age, length of neuroleptic treat ment, neuroleptic dose (converted to chlorpromazine units [12] ), clinical global impression (CGI) of overall severity of illness, and CGI therapeutic effect for male and female patients separately and for both sexes com bined. Table 2 shows the percentages of patients with tardive dyskinesia and parkinsonian symptoms. those being treated with antiparkinsonian medication and '< . fluphenazine, and those with a history of BCT treat-, ment, insulin treatment, brain damage, alcoholism. antidepressant treatment, and hospitalization.
. Three kinds of statistical analysis were performed "1 on the data. In each analysis the variable for tardive ~ .dyskinesia was regressed against the following vari-.:' abIes: age, number of years treated with neuroleptics,.L length of previous psychiatric hospitalizations, current ~ dosage of neuroleptics (converted to chlorpromazine·4i units), current fluphenazine treatment, total score fur parkinsonian symptoms, antiparkinsoniaD dosage.
nuinber of BCT treatments, number of insulin treat ments, presence of brain damage, alcoholism, history of antidepressant treatment, CGI overall severity of illness, and CGr therapeutic effect. 
uiables Predicting Incidence a/Tardive Dyskinesia
Patients were coded I or 0 according to whether tar ve dyskinesia was present or not; a regression analy i using the linear logistic model (13) related other riables to the probability ofthe patient's manifesting -dive dyskinesia. This analysis was carried out on all 1 patients by a computerized stepwise inclusion pro jUre (14) , which first determines the single most im rtant characteristic in predicting the incidence of dive dyskinesia, then the second most important .iable given that the first has been included in the lation, and so on. Table 3 shows the five variables that, when entered sequentially, made statistically sig nifican.t (p < .05) contributions to the regression rela tionship. The variable most related to the incidence of tardive dyskinesia was age, which was highly signifi cant (p<.OOl). Then followed length of time spent in a . psychiatric hospital. score for CGI therapeutic effect .
(a high score indicates little improvement, i.e., there tended to be a greater incidence of tardive dyskinesia among patients with little therapeutic improvement), fluphenazine treatment, and, finally, the total s~relor parkinsonian symptoms, which was related inversely to tardive dyskinesia (i.e., patients with fewer parkin sonian symptoms tended to have a higher incidence of tardive dyskinesia). When the score for tremors or the scores for both tremors and akathisia are excluded from the total score for parkinsonian symptoms, the inverse relationship between tardive dyskinesia and parkinsonian symptoms becomes more pronounced (see table 3 ). A test of goodness of fit of ~e model showed the fit to be satisfactory (x2=1.6, df=4, p=.8).
Variables Predicting Severity o/Tardive Dyskinesia
This analysis related the severity of tardive .dyski-' nesia, as measured by the total score, to the other vari · abIes by the usual multiple linear regression model. A first analysis was carried out on alI 261 patients by a computer program using a stepwise inclusion proce · dure (15) . Table 4 shows the six variables that, when ·entered sequentially, were significantly related to the total score for tardive dyskinesia. The same five vari ables found to be related to the incidence of tardive dyskinesia were also related to the severity of the dis order, although there is some change in their relative importance. Again, the. inverse relationship between tardive dyskinesia and .parkinsonian symptoms was mO.re pronounced when the score for tremors and aka thisia were excluded from the parkinsonism total score. In addition, the sex of the patient enters the re-' lation, with male patients tending to show more severe forms of the condition than female patients. The six variables included in the equation account for 18.5% of the total variation in the scores for tardive dyskinesia among the 261 patients.
Finally, we repeated this analysis including only those 80 patients who had tardive dyskinesia (table 4) . This analysis revealed that among the patients with tardive dyskinesia, those with previous brain damage tended to have more severe forms of the disorder.
. DISCUSSION I Recent surveys show a higher incidence of tardive dyskinesia than was first reported. In this study, tar i dive dyskinesia was found to be present in 31% of a popUlation of 261 schizophrenic outpatients treated by neuroleptics; this percentage is similar to that reported I by Fann and associates (7) . Age was. clearly the most important contributory factor;· older patients were more susceptible to tardive dyskinesia. It has also been our clinical experience that the older the patient is when first started on neuroieptics, the sooner he or she is likely to develop the syndrome. This would in dicate a need for caution when prescnbing neurolep tics to the elderly patient. A 1977 study (16) suggested biochemical changes in the striatum with aging, and it might be hypothesized that these changes could favor the appearance of tardive dyskinesia.
Among patients of the same age, those for whom neuroleptic treatment was producing little therapeutic effect w~re more likely to present severe forms of tar dive dyskinesia. When linked with the finding on age, this suggests that in some cases it may be beneficial to withdraw neuroleptics from older patients who are re sponding poorly to treatment.
Crane (2, 4) has reported that severe tardive dyski nesia is seldom observed in patients with severe par kinsonism. and vice-versa. Our findings support this, especially when tremors and akathisia are not included among the other parkinsonian symptoms. These two symptoms were excluded because our clinical experi ence has shown that a patient with tremors or akathisia may manifest tardive dyskinesia, whereas a patient with akinesia or rigidity seldom does. There tended to be a high incidence of tardive dyskinesia among pa tients being treated with fluphenazine (oral or enan thate). Although fluphenazine was the only piperazine drug given to these patients, one might expect this finding would also apply to the other piperazine-like drugs, which are responsible for a higher incidence of parkinsonian symptoms. It is possible that the hyper kinetic parkinsonian symptoms of tremor and aka thisia are precursors of hyperkinetic symptoms ofdys kinesia. Thus, these symptoms could be expected to coexist with dyskinetic symptoms in patients shifting from one syndrome to the other. In contrast, the hy 82 Am J Psychiatry 136:1. January 1979 pokinetic parkinsonian symptoms of rigidity and aki nesia could reduce or cover the expression of dyski nesia.
Tardive dyskinesia was more prevalent among pa tients who had spent longer periods of time in psychi atric hospitals (independent of their age). Since this variable appeared to be more important than the length of neuroleptic treatment, it may reflect the effect of regular high-dose neuroleptic administration in hospi tals. Similarly, the finding that patients responding poorly to neuroleptics had a higher incidence of tar dive dyskinesia might be related to past exposure to high neuroleptic doses. This would indicate that use of neuroleptics at higher than normal dosage should be limited to the most severe cases. However. the dose of neuroleptic currently received by the patient was not found to enter significantly into the regression relation ship. This is not unexpected, since high doses of neuroleptics are known to mask tardive dyskinesia. Previous brain damage tended to be present in the more severe cases of tardive dyskinesia· but was not found to be implicated in the appearance of the dis order. The overall incidence of tardive dyskinesia among brain-damaged patients was not higher than among patients with no brain damage. Since the most severe forms of dyskinesia are incapacitating, a his tory of brain damage would appear to be a relative contraindication to neuroleptic treatment. In the same way~ male patients also appeared to be more suscep ttble to severe forms of the disorder. Because men are often less responsive to neuroleptics than women, a possible explanation of their increased susceptibility to severe tardive dyskinesia is the use of higher neuro leptic dosage. Other. factors, such as EeT, insulin treatment, antiparkinsonian medication at the time of examination (which in the clinic is always adjusted so as not to aggravate the tardive dyskinesia), and history of tricyclic antidepressant treatment were not found to be related to tardive dyskinesia in this population of schizophrenic outpatients.
